Zobrazeno 1 - 6
of 6
pro vyhledávání: '"P W J Maljaars"'
Autor:
P W J Maljaars, J E Martens, E van Lingen, M E Tushuizen, D Diaz-Infante Morales, A E van der Meulen-de Jong, M E J Steenhuis, S van der Marel, T van Deynen, Ilse Molendijk
Publikováno v:
International Journal of Colorectal Disease, 37, 349-356. SPRINGER
Purpose Liver steatosis is a frequently reported condition in patients with inflammatory bowel disease (IBD). Different factors, both metabolic and IBD-associated, are believed to contribute to the pathogenesis. The aim of our study was to calculate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cc3b7edc1340a6cf72ab435701a89c9
https://hdl.handle.net/1887/3270955
https://hdl.handle.net/1887/3270955
Autor:
E, van Lingen, M E, Tushuizen, M E J, Steenhuis, T, van Deynen, J, Martens, D Diaz-Infante, Morales, A E, van der Meulen-de Jong, I, Molendijk, S, van der Marel, P W J, Maljaars
Publikováno v:
International journal of colorectal disease. 37(2)
Liver steatosis is a frequently reported condition in patients with inflammatory bowel disease (IBD). Different factors, both metabolic and IBD-associated, are believed to contribute to the pathogenesis. The aim of our study was to calculate the prev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f44280b4141be58e5d8bd02bfa0b6358
https://pubmed.ncbi.nlm.nih.gov/34791524
https://pubmed.ncbi.nlm.nih.gov/34791524
Autor:
J H Arkenbosch, E M J Beelen, G Dijkstra, M Romberg-Camps, M Duijvestein, F Hoentjen, S van der Marel, P W J Maljaars, S Jansen, N K de Boer, R West, C Horjus, L P S Stassen, F van Schaik, O van Ruler, B J H Jharap, N E Erler, M Doukas, A H A G Ooms, G Kats-Ugurlu, J van der Woude, A C De Vries
Publikováno v:
Journal of Crohn's and Colitis. 16:i316-i317
Background In patients with Crohn’s disease (CD), postoperative prophylactic medication based on clinical risk stratification is recommended in international guidelines to prevent recurrence after ileocolonic resection (ICR). This study aimed to ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97762df23a42a2564c6634b3e3dbb263
https://doi.org/10.1093/ecco-jcc/jjab232.411
https://doi.org/10.1093/ecco-jcc/jjab232.411
Autor:
T Straatmijer, V B C Biemans, D J A R Moes, F Hoentjen, R ter Heine, P W J Maljaars, R Theeuwen, M Pierik, M Duijvestein, A E van der Meulen
Publikováno v:
Journal of Crohn's and Colitis. 16:i340-i341
Background Ustekinumab (UST) is a monoclonal antibody which binds to the p40 subunit of interleukins-12/23 and is an effective and safe treatment for patients with Crohn’s disease (CD). An association between serum drug concentrations and therapeut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ffef8551b5b619b4209ac89f6dcd8bc
https://doi.org/10.1093/ecco-jcc/jjab232.444
https://doi.org/10.1093/ecco-jcc/jjab232.444
Autor:
P W J Maljaars, Laurents P. S. Stassen, J Arkenbosch, Marjo J E Campmans-Kuijpers, Rachel West, Gerard Dijkstra, Mariëlle Romberg-Camps, O. van Ruler, Frank Hoentjen, S Jansen, K van Dongen, Bindia Jharap, S van der Marel, C.J. van der Woude, A C de Vries, M Ruiterkamp
Publikováno v:
Journal of Crohn's and Colitis. 15:S278-S279
Background Prehabilitation strategies to improve the postoperative course after intestinal resections in Crohn’s disease (CD) are mostly non-evidence-based. Prehabilitation strategies may include preoperative nutritional, physical and psychological
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af65911da5fadb17ffde9280a9f3b77a
https://doi.org/10.1093/ecco-jcc/jjab076.354
https://doi.org/10.1093/ecco-jcc/jjab076.354
Autor:
G.-P. Pageaux, P W J Maljaars, R. Altwegg, M J Westerouen van Meeteren, B. van Hoek, Daniel J. Stein, T. Stijnen, Akin Inderson, Bu'Hussain Hayee, A. Van der Meulen
Publikováno v:
Journal of Crohn's and Colitis, 11(9), 1146-1151
Background and aim Little is known about the risk of serious infection when combining anti-tumour necrosis factor [TNF] therapy for refractory inflammatory bowel disease [IBD] with immunosuppression after liver transplantation [LT]. Our aim was to in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c67eee5819fbda23f59237ebc91820ba
http://hdl.handle.net/1887/117528
http://hdl.handle.net/1887/117528